Expert Ratings for Iovance Biotherapeutics
Portfolio Pulse from Benzinga Insights
Iovance Biotherapeutics (NASDAQ:IOVA) has received predominantly bullish ratings from analysts in the last quarter. The average 12-month price target for the company has increased by 49.64% over the past month, currently standing at $27.31.
August 09, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iovance Biotherapeutics has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment and can impact a company's stock price. In the case of Iovance Biotherapeutics, the predominantly bullish ratings and the significant increase in the average 12-month price target suggest a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100